EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome

Gabriele Mortari, Carolina Bigatti, Giulia Proietti Gaffi, Barbara Lionetti, Andrea Angeletti, Simona Matarese, Enrico Eugenio Verrina, Gianluca Caridi, Francesca Lugani, Valerio Gaetano Vellone, Decimo Silvio Chiarenza, Edoardo La Porta

Pediatric Nephrology · 2025

DOI: 10.1007/s00467-024-06480-9 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Gabriele Mortari und 11 weiteren Autor:innen. Beteiligte Einrichtung: UOC of Nephrology, Dialysis and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Hauptthemen laut MEDLINE: Atypical Hemolytic Uremic Syndrome, Complement C3b Inactivator Proteins, Complement Factor H, Escherichia coli Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis. It can be classified as either typical, primarily caused by Shiga toxin-producing Escherichia coli (STEC) infection, or as atypical HUS (aHUS), which results from uncontrolled complement activation.

Methods

We report the case of a 9-year-old boy with aHUS due to compound heterozygous complement factor H-related genes (CFHR) 1/3 and CFHR1 – CFHR4 deletions, leading to the development of anti-complement factor H (CFH) autoantibodies. The patient presented nephrological and neurological thrombotic microangiopathy with STEC positivity. Additionally, we provide an extensive literature review of aHUS cases initially classified as typical.

Results

A total of 11 patients were included, 73% of whom were pediatric. Kidney replacement therapy was required in 73% of patients. The recurrence rate was 55%. All cases were found positive for pathological variants of the complement system genes. The most commonly implicated gene was CFH , while the CFHR genes were involved in 36% of cases, although none exhibited anti-CFH autoantibodies. Anti-complement therapy was administered in 54% of cases, and none of the patients who received it early progressed to kidney failure.

Conclusions

STEC infection does not exclude aHUS diagnosis, and early use of anti-complement therapy might be reasonable in life-threatening conditions. Genetic testing can be helpful in patients with atypical presentations and can confirm the necessity of prolonged anti-complement therapy. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atypical Hemolytic Uremic SyndromeComplement C3b Inactivator ProteinsComplement Factor HEscherichia coli InfectionsShiga-Toxigenic Escherichia coliChildHumansMaleAutoantibodiesBlood ProteinsApolipoproteins

Stichwörter der Autor:innen

Anti-CFH antibodyAnti-complement therapyAtypical HUSCFHREculizumabSTEC-HUS

Substanzen

AutoantibodiesBlood ProteinsComplement C3b Inactivator ProteinsComplement Factor HCFH protein, humanCFHR1 protein, humanCFHR3 protein, humanCFHR4 protein, humanApolipoproteins

Autor:innen und Institutionen

  • UOC of Nephrology, Dialysis and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
  • UOC of Nephrology, Dialysis and Transplantation, ASST Spedali Civili, Brescia, Italy.
  • Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
  • UOC of Nephrology, Dialysis and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Francescalugani@gaslini.org.
  • UOC of Pathology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Zitieren

APA

Mortari, G., Bigatti, C., Gaffi, G. P., Lionetti, B., Angeletti, A., Matarese, S., Verrina, E. E., Caridi, G., Lugani, F., Vellone, V. G., Chiarenza, D. S., & La Porta, E. (2025). Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06480-9

Vancouver

Mortari G, Bigatti C, Gaffi GP, Lionetti B, Angeletti A, Matarese S, et al. Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome. Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06480-9

BibTeX
@article{Mortari2025,
  author = {Mortari, Gabriele and Bigatti, Carolina and Gaffi, Giulia Proietti and Lionetti, Barbara and Angeletti, Andrea and Matarese, Simona and Verrina, Enrico Eugenio and Caridi, Gianluca and Lugani, Francesca and Vellone, Valerio Gaetano and Chiarenza, Decimo Silvio and La Porta, Edoardo},
  title = {Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome},
  journal = {Pediatric Nephrology},
  year = {2025},
  doi = {10.1007/s00467-024-06480-9}
}
Kostenlos starten →